Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

docun	nents given to ASX become ASX's property a	ınd may be made public.	
Introdu	ced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99), 1/7/2000, 30/9/2001, £1/3/2002, 1/1/2003, 24/10/2005.	
	of entity		
CC	OMPUMEDICS LIMITED		
ABN			
95	006 854 897		
We ((the entity) give ASX the following i	information.	
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).			
1	*Class of *securities issued or to be issued	Convertible Redeemable Notes	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,000	
3	Principal terms of the *securities (eg,	Deducanable at issue mice or convertible at	
3	if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Redeemable at issue price or convertible at conversion price, being the average share price on 5 trading days preceding issue date. 2 year term. Convertible 1 year and 2 years from date of issue. Convertibility is subject to shareholder approval.	

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

otherwise a default interest rate of 14.5% applies.

Interest payable at coupon rate of 20% per

annum, subject to shareholder approval,

Interest payable as equity at conversion price. No participation in any dividends.

5 Issue price or consideration

\$1,000.00 per note

No. New securities.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Issued for general working capital.

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

16 March 2006

8 Number and *class of all *securities quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
140,000,000	Ordinary shares

		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the securities in clause 2 if applicable)	1,000	Redeemable convertible notes
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No dividends payable	
Part	2 - Bonus issue or pro r	ata issue	
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	*Class of *securities to which the offer relates		
15	*Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		
18	Names of countries in which the entity has *security holders who will not be sent new issue documents		
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations		

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	N1	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
	Consussion	
22	Names of any brokers to the issue	
	<u> </u>	
23	Fee or commission payable to the	
	broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances	
	or renunciations on behalf of	
	+security holders	
25	**	
25	If the issue is contingent on *security holders' approval, the date	
	of the meeting	
26	Date entitlement and acceptance	
	form and prospectus or Product Disclosure Statement will be sent to	
	persons entitled	
27	If the entity has issued options, and	
	the terms entitle option holders to participate on exercise, the date on	
	which notices will be sent to option	
	holders	
28	Data rights trading will have GC	
40	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if	
	applicable)	
	<u> </u>	
30	How do *security holders sell their	
	entitlements in full through a broker?	
31	How do *security holders sell part	
	of their entitlements through a	
	broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

32	their	do *security holders dispose of entitlements (except by sale gh a broker)?	
33	*Desp	oatch date	
		uotation of securities	
34	Type (tick o	of securities one)	
(a)		Securities described in Part 1	
(b)			I of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
Entiti	es tha	t have ticked box 34(a)	
Addit	ional s	ecurities forming a new c	lass of securities
Tick to docume		e you are providing the inform	ation or
35		-	y securities, the names of the 20 largest holders of the e number and percentage of additional *securities held by
36			ity securities, a distribution schedule of the additional nber of holders in the categories
37		A copy of any trust deed for	the additional *securities

⁺ See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of securities for which +quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	†Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will
 not require disclosure under section 707(3) or section 1012C(6) of the
 Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Director/Company secretar	Date: y)	30 March,	, 2006.
Print name:	David Lawson			